- Home
- LODE vs TLSA Comparison
LODE vs TLSA Comparison
Compare LODE & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LODE | TLSA |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 182.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | LODE | TLSA |
|---|---|---|
| Price | $3.62 | $1.49 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 372.0K |
| Earning Date | 10-30-2025 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,778,445.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,798.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.99 | N/A |
| 52 Week Low | $1.67 | $0.63 |
| 52 Week High | $6.13 | $2.60 |
Technical Indicators
Market Signals| Indicator | LODE | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 42.96 |
| Support Level | $3.81 | $1.44 |
| Resistance Level | $4.10 | $1.58 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 25.19 | 50.46 |
Price Performance
Historical ComparisonAbout LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.